Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Trinity Biotech ( (TRIB) ) has provided an announcement.
Trinity Biotech has announced that it received early approval from the World Health Organization to commence offshore manufacturing of its rapid HIV tests, TrinScreen HIV and Uni-Gold HIV. This milestone is part of the company’s Comprehensive Transformation Plan aimed at reducing manufacturing costs and is expected to enhance future growth, improve profit margins, and increase shareholder value as they begin production at the new location in the first quarter of 2025.
More about Trinity Biotech
Trinity Biotech is a commercial-stage biotechnology company specializing in human diagnostics and diabetes management solutions, including wearable biosensors. The company develops and markets diagnostic systems for the point-of-care and clinical laboratory segments, focusing on infectious diseases and diabetes-related metrics. Trinity Biotech operates globally, selling directly in the United States and through international distributors in over 75 countries.
YTD Price Performance: -60.47%
Average Trading Volume: 172,111
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.63M
See more insights into TRIB stock on TipRanks’ Stock Analysis page.
